



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Wlassof et al.

SERIAL NUMBER : 10/500,171

EXAMINER : Jezia Riley

FILING DATE : December 22, 2004

ART UNIT : 1637

FOR : ENZYMATIC REDOX LABELLING OF NUCLEIC ACIDS

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the above-referenced patent application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Copies of cited references B1-2; C1-4; and
4. Return postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617-542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 28616-002 NATL. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

IA Beattie

Ingrid A Beattie, Reg. No. 42,306

Attorney for Applicants

c/o MINTZ, LEVIN

Address all written correspondence to

Customer no.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Dated: June 15, 2006


Express Mail Label No.: EV 460367402 US
Date of Deposit: June 15, 2006

Attorney Docket No.: 28616-002 NATL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Wlassof et al.
SERIAL NUMBER : 10/500,171
FILING DATE : December 22, 2004
FOR : ENZYMATIC REDOX LABELLING OF NUCLEIC ACIDS

EXAMINER : Jezia Riley
ART UNIT : 1637



Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed due.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANTS: Wlassof et al.
U.S.S.N.: 10/500,171

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 28616-002 NATL.

Respectfully submitted,



Ingrid A Beattie, Reg. No. 42,306
Attorney for Applicants
c/o MINTZ, LEVIN
Address all written correspondence to
Customer no.: 30623
Tel: (617) 542-6000
Fax: (617) 542-2241

Date: June 15, 2006

TRA 2163392v.1

Express Mail No.: EV 460367402 US
Date of Deposit: June 15, 2006



Page 1 of 1
Attorney Docket No.: 28616-002 NATL

Please type a plus sign (+) in this box



PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/500,171
	Filing Date	December 22, 2004
	First Named Inventor	Wlassof et al.
	Group Art Unit	1637
	Examiner Name	Jezia Riley
	Attorney Docket Number	28616-002 NATL

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

U.S. PUBLISHED APPLICATION DOCUMENTS

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1	WO 92/02533	CHIRON CORPORATION	02/20/92	
	B2	WO 99/09045	SOMAGENICS, INC.	02/25/99	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Telser et al. <i>J. Am. Chem. Soc.</i> , 111:7221-7226 (1989)
	C2	Tierney et al. <i>Org. Lett.</i> , 2(22):3413-3416 (2000)
	C3	Yu et al. <i>J. Am. Chem. Soc.</i> , 122:6767-6768 (2000)
	C4	International Search Report for PCT/AU02/01767, mailed March 4, 2003

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.